Form 4: Scholar Rock Director Kristina Burow Receives Equity Grant

Director Kristina Burow acquired 6,839 restricted stock units and 4,310 stock options as part of an equity compensation grant.

Summary

• Director Kristina Burow was granted 6,839 restricted stock units (RSUs) on June 4, 2026.
• The director also received 4,310 stock options with an exercise price of $45.33.
• The RSUs vest on the earlier of June 15, 2027, or the date of the next Annual Meeting.
• The stock options vest on the earlier of the first anniversary of the grant or the date of the next Annual Meeting.
• Following the transaction, the director holds 117,710 shares directly and maintains an indirect interest in 2,345,711 shares held by ARCH Venture Fund VIII, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Continued commitment of a managing director from a major venture capital backer.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though standard for corporate governance.

Risks

• Vesting is subject to continued service, creating potential turnover risk if the director departs before the vesting date.

Future Outlook

The equity grants are subject to standard vesting schedules tied to continued service through the next Annual Meeting or the first anniversary of the grant.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between independent directors and long-term corporate strategy.

Comparison to Industry Standards

• The grant structure follows standard industry practices for non-employee director compensation in mid-cap biotech firms.
• Vesting periods tied to annual meetings are consistent with typical corporate governance policies for public life sciences companies.

Related Party Transactions

• The reporting person is a managing director of the general partner of ARCH Venture Fund VIII, L.P., which holds a significant stake in the issuer.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on June 15, 2027, or the next Annual Meeting.
• Vesting of stock options on the first anniversary of the grant or the next Annual Meeting.

Key Dates

Keywords

Scholar Rock, SRRK, Form 4, Insider Trading, Equity Compensation, Director Compensation, Biotech